{"id":"hexobarbital","rwe":[{"pmid":"37805261","year":"2023","title":"General intravenous anesthetics - pharmacodynamics, pharmacokinetics and chiral properties.","finding":"","journal":"Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti","studyType":"Clinical Study"},{"pmid":"37380443","year":"2023","title":"Modeled Rat Hepatic and Plasma Concentrations of Chemicals after Virtual Administrations Using Two Sets of in Silico Liver-to-Plasma Partition Coefficients.","finding":"","journal":"Biological & pharmaceutical bulletin","studyType":"Clinical Study"},{"pmid":"36868027","year":"2023","title":"New approach for barbiturates, phenytoin, methyprylon and glutethimide determination and fragmentation (UHPLC-MS/MS).","finding":"","journal":"Journal of pharmaceutical and biomedical analysis","studyType":"Clinical Study"},{"pmid":"36498900","year":"2022","title":"Mechanisms of Susceptibility and Resilience to PTSD: Role of Dopamine Metabolism and BDNF Expression in the Hippocampus.","finding":"","journal":"International journal of molecular sciences","studyType":"Clinical Study"},{"pmid":"34822961","year":"2022","title":"Ayahuasca blocks ethanol preference in an animal model of dependence and shows no acute toxicity.","finding":"","journal":"Journal of ethnopharmacology","studyType":"Clinical Study"}],"tags":[{"label":"hexobarbital","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"GABA-A receptor alpha-1/beta-3/gamma-2","category":"target"},{"label":"GABRA1","category":"gene"},{"label":"GABRB3","category":"gene"},{"label":"GABRG2","category":"gene"},{"label":"N01AF02","category":"atc"},{"label":"Active","category":"status"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Central Nervous System Depressants","category":"pharmacology"},{"label":"GABA Agents","category":"pharmacology"},{"label":"GABA Modulators","category":"pharmacology"},{"label":"Hypnotics and Sedatives","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=HEXOBARBITAL","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:31:24.591318+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:31:29.883239+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=HEXOBARBITAL","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:31:30.181697+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL7728/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:31:30.965355+00:00"}},"allNames":"barbidorm","offLabel":[],"synonyms":["hexobarbital","barbidorm","hexobarbitone","methexenyl","methylhexabarbital","methylhexabital"],"timeline":[{"date":"1932-01-01","type":"positive","source":"DrugCentral","milestone":"YEAR INTRODUCED approval"}],"approvals":[{"date":"1932-01-01","orphan":false,"company":"","regulator":"YEAR INTRODUCED"}],"brandName":"Barbidorm","ecosystem":[],"mechanism":{"target":"GABA-A receptor alpha-1/beta-3/gamma-2, GABA-A receptor alpha-2/beta-3/gamma-2, GABA-A receptor alpha-3/beta-3/gamma-2","targets":[{"gene":"GABRA1","source":"DrugCentral","target":"GABA-A receptor alpha-1/beta-3/gamma-2","protein":"Gamma-aminobutyric acid receptor subunit alpha-1"},{"gene":"GABRB3","source":"DrugCentral","target":"GABA-A receptor alpha-1/beta-3/gamma-2","protein":"Gamma-aminobutyric acid receptor subunit beta-3"},{"gene":"GABRG2","source":"DrugCentral","target":"GABA-A receptor alpha-1/beta-3/gamma-2","protein":"Gamma-aminobutyric acid receptor subunit gamma-2"},{"gene":"GABRA2","source":"DrugCentral","target":"GABA-A receptor alpha-2/beta-3/gamma-2","protein":"Gamma-aminobutyric acid receptor subunit alpha-2"},{"gene":"GABRA3","source":"DrugCentral","target":"GABA-A receptor alpha-3/beta-3/gamma-2","protein":"Gamma-aminobutyric acid receptor subunit alpha-3"},{"gene":"GABRA5","source":"DrugCentral","target":"GABA-A receptor alpha-5/beta-3/gamma-2","protein":"Gamma-aminobutyric acid receptor subunit alpha-5"}],"modality":"Small Molecule","drugClass":"hexobarbital","explanation":"","oneSentence":"","technicalDetail":"Barbitone acts as a positive allosteric modulator of the GABA-A receptor, increasing the frequency of chloride channel opening and enhancing the inhibitory effects of GABA on neuronal excitability."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1369","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=HEXOBARBITAL","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T14:57:14.380807","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:31:32.934049+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"methohexital","drugSlug":"methohexital","fdaApproval":"1960-06-27","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"thiopental","drugSlug":"thiopental","fdaApproval":"","patentStatus":"Unknown","relationship":"same-class"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"hexobarbital","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"methohexital","brandName":"methohexital","genericName":"methohexital","approvalYear":"1960","relationship":"same-class"},{"drugId":"thiopental","brandName":"thiopental","genericName":"thiopental","approvalYear":"","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"NUI":"N0000147126","NDDF":"001424","UNII":"AL8Z8K3P6S","VUID":"4018823","CHEBI":"CHEBI:5706","VANDF":"4018823","INN_ID":"2086","RXNORM":"5302","UMLSCUI":"C0019469","chemblId":"CHEMBL7728","ChEMBL_ID":"CHEMBL7728","KEGG_DRUG":"D01071","DRUGBANK_ID":"DB01355","PUBCHEM_CID":"3608","SNOMEDCT_US":"423380000","MESH_DESCRIPTOR_UI":"D006591"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"4.9 hours","clearance":"3.4 mL/min/kg","bioavailability":"95%","fractionUnbound":"0.53%","volumeOfDistribution":"1.1 L/kg"},"publicationCount":1320,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"N01AF02","allCodes":["N01AF02","N05CA16"]},"biosimilarFilings":[],"recentPublications":[{"date":"2023 Fall","pmid":"37805261","title":"General intravenous anesthetics - pharmacodynamics, pharmacokinetics and chiral properties.","journal":"Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti"},{"date":"2023 Sep 1","pmid":"37380443","title":"Modeled Rat Hepatic and Plasma Concentrations of Chemicals after Virtual Administrations Using Two Sets of in Silico Liver-to-Plasma Partition Coefficients.","journal":"Biological & pharmaceutical bulletin"},{"date":"2023 May 10","pmid":"36868027","title":"New approach for barbiturates, phenytoin, methyprylon and glutethimide determination and fragmentation (UHPLC-MS/MS).","journal":"Journal of pharmaceutical and biomedical analysis"},{"date":"2022 Nov 23","pmid":"36498900","title":"Mechanisms of Susceptibility and Resilience to PTSD: Role of Dopamine Metabolism and BDNF Expression in the Hippocampus.","journal":"International journal of molecular sciences"},{"date":"2022 Mar 1","pmid":"34822961","title":"Ayahuasca blocks ethanol preference in an animal model of dependence and shows no acute toxicity.","journal":"Journal of ethnopharmacology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"withdrawn","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"OTHER","regulator":"YEAR INTRODUCED","status":"approved","approval_date":"1932-01-01T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:31:32.934049+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":false,"score":0}}